Related Experiment Videos
Interstitial lung disease associated with gefitinib
Kensuke Kataoka1, Hiroyuki Taniguchi, Yoshinori Hasegawa
1Department of Medicine, Division of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.
Respiratory Medicine
|September 3, 2005
Summary
Gefitinib-induced interstitial lung disease (ILD) can occur rapidly in lung cancer patients. Early detection via imaging and symptom monitoring, along with corticosteroid treatment, can lead to resolution, with potential Th1 inflammation involvement.
Area of Science:
- Pulmonology
- Oncology
- Pharmacology
Background:
- Pulmonary toxicity from gefitinib, an epidermal growth factor receptor inhibitor, is a known concern.
- Clinical data and mechanistic understanding of gefitinib-induced interstitial lung disease (ILD) are limited.
Purpose of the Study:
- To investigate clinical characteristics and potential mechanisms of gefitinib-induced ILD.
- To provide recommendations for monitoring and management of this adverse event.
Main Methods:
- Retrospective review of 489 lung cancer patients treated with gefitinib.
- Diagnosis of ILD in four patients based on clinical records, chest X-rays, fiberoptic bronchoscopy, and bronchoalveolar lavage (BAL).
- Analysis of BAL fluid for inflammatory markers, including interferon-inducible protein-10 (IP-10).
Main Results:
- Gefitinib-induced ILD manifested rapidly after treatment initiation.
- High levels of IP-10 were detected in BAL fluid of affected patients.
- All four patients responded well to high-dose corticosteroid therapy, achieving ILD resolution.
Conclusions:
- Close monitoring of chest imaging and respiratory symptoms is crucial for early gefitinib-induced ILD detection.
- A Th1-type inflammatory response may contribute to the pathogenesis of gefitinib-induced ILD.
- Prompt corticosteroid treatment is effective in resolving gefitinib-induced ILD.